Monika Jermann

Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma

Walter Weder, Rolf A. Stahel, J. Bernhard et al. · Annals of Oncology · 2007 · 318 citations · Full text

Surgical Oncology, Malignant Pleural Mesothelioma, Medicine +6

Circulating Deoxyribonucleic Acid As Prognostic Marker in Non–Small-Cell Lung Cancer Patients Undergoing Chemotherapy

Oliver Gautschi, Colette Bigosch, Barbara Huegli et al. · Journal of Clinical Oncology · 2004 · 286 citations · Full text

Rituximab–EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study

Monika Jermann, L.M. Jost, Ch. Taverna et al. · Annals of Oncology · 2004 · 100 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Effective Salvage Therapy +9

A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma

Monika Jermann, Rolf A. Stahel, Marc Salzberg et al. · Cancer Chemotherapy and Pharmacology · 2005 · 58 citations

Urology, Renal-cell Carcinoma, Phase Ii +6

Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients

Oliver Gautschi, Barbara Hügli, Annemarie Ziegler et al. · Lung Cancer · 2006 · 37 citations

Tobacco Control, Cancer Risk, Cyclin D1 +9